The estimated Net Worth of Jean Luc Belingard is at least $9.22 Milhão dollars as of 6 February 2024. Mr. Belingard owns over 947 units of Labcorp stock worth over $3,902,152 and over the last 19 years he sold LH stock worth over $5,024,655. In addition, he makes $289,866 as Independent Director at Labcorp.
Sign up
Mr. Belingard LH stock SEC Form 4 insiders trading
Jean has made over 18 trades of the Labcorp stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 947 units of LH stock worth $206,721 on 6 February 2024.
The largest trade he's ever made was selling 26,479 units of Labcorp stock on 19 February 2020 worth over $5,024,655. On average, Jean trades about 650 units every 59 days since 2005. As of 6 February 2024 he still owns at least 17,876 units of Labcorp stock.
You can see the complete history of Mr. Belingard stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jean-Luc Belingard biography
Jean-Luc Belingard serves as Independent Director of the Company. He has served as a director of the Company since April 28, 1995. Mr. Bélingard currently serves as Operating Advisor to Clayton, Dubilier & Rice, a private equity investment firm, since October 2019. From 2011 to December 2017, Mr. Bélingard served as Chairman and CEO of bioMérieux (Président Directeur Général), the worldwide leader of the IVD microbiology segment and a non-U.S. public company. Mr. Bélingard continues to serve on the board of directors of bioMérieux and as Vice President of Institut Mérieux. Mr. Bélingard retired as Chairman and Chief Executive Officer of Ipsen SA, a diversified French healthcare holding company, on November 22, 2010. He had served in that position since 2002. Prior to this position, Mr. Bélingard was Chief Executive Officer from 1999 to 2001 of bioMérieux-Pierre Fabre, a diversified French healthcare holding company, where his responsibilities included the management of that company’s worldwide pharmaceutical and cosmetic business. From 1990 to 1999, Mr. Bélingard was Chief Executive Officer of Roche Diagnostics and a member of the Hoffman La Roche group Executive Committee. Mr. Bélingard is a director of Lupin Limited (India), a non-U.S. public company. Mr. Bélingard is also a director at Transgene SA an Institut Mérieux company. Mr. Bélingard serves on the board of Laboratoire Pierre Fabre S.A. (France) since 2013, which is owned by The Pierre Fabre Foundation, a government-recognized public organization. Mr. Bélingard is also a member of the Bill and Melinda Gates Foundation CEO Roundtable and has served on the Novo Advisory Group of Novo Holdings since 1998. Mr. Bélingard was Chairman of “FEFIS,” the French Federation of Health Industries (Fédération Française des Industries de Santé) from 2016 to December 2019, and, since January 2017, he has been a member of the Conseil National de l’Industrie (C.N.I.) chaired by the French government.
What is the salary of Jean Belingard?
As the Independent Director of Labcorp, the total compensation of Jean Belingard at Labcorp is $289,866. There are 14 executives at Labcorp getting paid more, with Glenn Eisenberg having the highest compensation of $8,822,760.
How old is Jean Belingard?
Jean Belingard is 71, he's been the Independent Director of Labcorp since 1995. There are no older and 24 younger executives at Labcorp.
What's Jean Belingard's mailing address?
Jean's mailing address filed with the SEC is 531, South Spring Street, Burlington, Alamance County, North Carolina, 27215, United States.
Insiders trading at Labcorp
Over the last 19 years, insiders at Labcorp have traded over $236,972,149 worth of Labcorp stock and bought 10,666 units worth $1,520,331 . The most active insiders traders include Mahon Thomas P Mac, Garheng Kong, eDavid P King. On average, Labcorp executives and independent directors trade stock every 11 days with the average trade being worth of $2,652,442. The most recent stock trade was executed by Der Vaart Sandra D Van on 19 August 2024, trading 2,000 units of LH stock currently worth $454,100.
What does Labcorp do?
recognized for our innovation, quality, and customer convenience, labcorp delivers timely, accurate results for improved patient care. with scientific expertise in esoteric testing, genomics, and clinical and anatomic pathology, labcorp performs more than one million tests on approximately 400,000 samples each day. labcorp is a pioneer in applying advances in medicine and science to laboratory testing, with more than 35 years of experience in serving physicians and their patients. labcorp operates a sophisticated laboratory network, with corporate headquarters in burlington, nc, and more than 34,000 employees worldwide. our more than 220,000 clients include physician offices, hospitals, managed care organizations, and biotechnology and pharmaceutical companies. laboratory corporation of america holdings is listed on the new york stock exchange (nyse) under ticker symbol lh.
What does Labcorp's logo look like?
Complete history of Mr. Belingard stock trades at Labcorp
Labcorp executives and stock owners
Labcorp executives and other stock owners filed with the SEC include:
-
Glenn Eisenberg,
Chief Financial Officer, Executive Vice President -
Adam Schechter,
President, Chief Executive Officer, Director -
Adam H. Schechter,
Pres, CEO & Chairman -
Brian Caveney,
Executive Vice President, President, Diagnostics and Chief Medical Officer -
Lance Berberian,
Executive Vice President, Chief Technology Officer, Chief Information Officer -
Mark Schroeder,
Executive Vice President, President of Diagnostics Laboratory Operations and Global Supply Chain -
Glenn A. Eisenberg,
CFO & Exec. VP -
Mark S. Schroeder,
Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain -
Dr. Paul R. Kirchgraber M.D.,
Exec. VP & CEO of Covance Drug Devel. -
Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH,
Exec. VP, Pres of Diagnostics & Chief Medical Officer -
Peter Neupert,
Lead Independent Director -
Kerrii Anderson,
Independent Director -
Garheng Kong,
Independent Director -
Robert Williams,
Independent Director -
Richelle Parham,
Independent Director -
D. Gary Gilliland,
Independent Director -
Jean-Luc Belingard,
Independent Director -
Jeffrey Davis,
Independent Director -
Clarissa Willett,
Vice President, Investor Relations -
Peter Wilkinson,
Senior Vice President, Chief Accounting Officer -
Paul Kirchgraber,
Executive Vice President and Chief Executive Officer - Covance Drug Development -
Sandra Van Der Vaart,
Executive Vice President, Chief Legal Officer, Chief Compliance Officer and Secretary -
Amy Summy,
Executive Vice President, Chief Marketing Officer -
Judith Seltz,
Chief Human Resource Officer, Executive Vice President -
Chas Cook,
VP of Investor Relations -
Dr. Marcia T. Eisenberg Ph.D.,
Chief Scientific Officer & Sr. VP -
Lance V. Berberian,
Exec. VP and Chief Information & Technology Officer -
Peter J. Wilkinson,
Sr. VP & Chief Accounting Officer -
Dr. Michelle Abelson Ph.D.,
Laboratory Director of Operations -
Anita Z Graham,
EVP, CHRO -
R Sanders Williams,
Director -
Edward T Dodson,
Principal Accounting Officer -
Lisa J Uthgenannt,
Chief Human Resources Officer -
David P King,
Director -
M. Huff Gary,
CEO, LabCorp Diagnostics -
John D Ratliff,
CEO, Covance Drug Development -
F Samuel Iii Eberts,
Chief Legal Officer, Secretary -
Robert E Jr Mittelstaedt,
Director -
Kathryn E Wengel,
Director -
Thomas Pike,
Pres & CEO Clinical Business -
Arthur H Rubenstein,
Director -
M Keith Weikel,
Director -
William B Hayes,
Sr. Vice President -
Wendy E Lane,
Director -
Lidia Fonseca,
Chief Information Officer -
Bradford T Smith,
EVP, Chf Legal Offcr,Secretary -
Don M Hardison,
EVP, COO -
Mahon Thomas P Mac,
CEO and Chairman of the Board -
N Anthony Coles,
Director -
William Haas,
EVP, Sales & Marketing -
Andrew J Conrad,
EVP, Chief Scientific Officer -
Goldman Myla Lai,
EVP & Chief Medical Officer -
Benjamin R Miller,
EVP, Oncology Products & Serv -
Andrew G Wallace,
Director -
Allen W Troub,
EVP, Western Operations -
Woodrow L Cook,
EVP, Eastern Operations -
Richard L Novak,
EVP & Strategic Planning -
Deborah L Keller,
CEO, Covance Drug Development -
James T. Jr. Boyle,
Senior Vice President -
Joseph L Herring,
CEO of Covance Drug Division -
Mark E Brecher,
Chief Medical Officer -
Kirsten Marie Kliphouse,
Director -
Paul Rothman,
Director -
Jonathan P. Di Vincenzo,
EVP, Pres, Central Labs & Intl -
Megan D. Bailey,
EVP, Chief Strategy Officer